Apoptotic and necrotic effects of tumour necrosis factor-alpha potentiated with hyperthermia on L929 and tumour necrosis factor-alpha-resistant L929

References

• Carswell EA, Old LJ, Kassel RL, Green S, Fiore H, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–3670
   PubMed Web of Science ®Google Scholar
• Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630–632
   PubMed Web of Science ®Google Scholar
• Spriggs DR, Yates SW. Tumor necrosis factor: The molecules and their emerging role in medicine. Tumor necrosis factor: The molecules and their emerging role in medicine, B Beutler. Raven Press, New York 1992; 383–406
   Google Scholar
• Van Ostade X, Tavernier J, Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Eng 1994; 7: 5–22
   PubMedGoogle Scholar
• Tomasovic SP, Barta M, Klostergaard J. Neutral red uptake and clonogenic survival assays of the hyperthermic sensitization of tumor cells to tumor necrosis factor. Radiat Res 1989; 119: 325–337
   PubMed Web of Science ®Google Scholar
• Tomasovic SP, Barta M, Klostergaard J. Temporal dependence of hyperthermic augmentation of macrophage-TNF production and tumor cell-TNF sensitization. Int J Hyperthermia 1989; 5: 625–639
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988; 48: 650–653
   PubMed Web of Science ®Google Scholar
• Tomasovic SP, Vasey TA, Story MD, Stephens LC, Klostergaard J. Cytotoxic manifestations of the interaction between hyperthermia and TNF: DNA fragmentation. Int J Hyperthermia 1994; 10: 247–262
   PubMed Web of Science ®Google Scholar
• Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, Persiani L, Santinami M, Santoro N, Cascinelli N. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994; 73: 483–492
   PubMed Web of Science ®Google Scholar
• Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993; 80: 995–997
   PubMed Web of Science ®Google Scholar
• Alexander HR, Jr. Isolation perfusion. Cancer: Principles and practice of oncology, VT De Vita, Jr, S Hellman, SA Rosenberg. Lippincott, Williams & Wilkins, Philadelphia 2001; 769–776
   Google Scholar
• Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005; 12: 609–615
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Rossi CR, Santinami M, Cavaliere F, Garinei R, Anzà M, Perri P, Botti C, Di Angelo P, Pasqualoni R, Di Filippo S. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. In Vivo 2006; 20: 739–742
   PubMedGoogle Scholar
• Hayes AJ, Neuhaus SJ, Clark MA, Thomas JM. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007; 14: 230–238
   PubMed Web of Science ®Google Scholar
• Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008; 24: 193–203
   PubMed Web of Science ®Google Scholar
• Kong SK, Suen YK, Chan YM, Chan CW, Choy YM, Fung KP, Lee CY. Concanavalin A-induced apoptosis in murine macrophages through a Ca(2+)-independent pathway. Cell Death Differ 1996; 3: 307–314
   PubMedGoogle Scholar
• van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1–9
   PubMedGoogle Scholar
• Niitsu Y, Watanabe N, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 1988; 48: 654–657
   PubMed Web of Science ®Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-1 alpha and TNF-alpha potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996; 12: 335–344
   PubMed Web of Science ®Google Scholar
• Rubin BY, Smith LJ, Hellermann GR, Lunn RM, Richardson NK, Anderson SL. Correlation between the anticellular and DNA fragmenting activities of tumor necrosis factor. Cancer Res 1988; 48: 6006–6010
   PubMed Web of Science ®Google Scholar
• Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 1989; 49: 1644–1648
   PubMed Web of Science ®Google Scholar
• Bellomo G, Perotti M, Taddei F, Mirabelli F, Finardi G, Nicotera P, Orrenius S. Tumor necrosis factor alpha induces apoptosis in mammary adenocarcinoma cells by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res 1992; 52: 1342–1346
   PubMed Web of Science ®Google Scholar
• Leist M, Jäättelä M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589–598
   PubMed Web of Science ®Google Scholar
• Gerschenson LE, Rotello RJ. Apoptosis: A different type of cell death. FASEB J 1992; 6: 2450–2455
   PubMed Web of Science ®Google Scholar
• Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of apoptosis. Int Rev Cytol 1980; 68: 251–306
   PubMedGoogle Scholar
• Kokura S, Yoshida N, Ueda M, Imamoto E, Ishikawa T, Takagi T, Naito Y, Okanoue T, Yoshikawa T. Hyperthermia enhances tumor necrosis factor alpha-induced apoptosis of a human gastric cancer cell line. Cancer Lett 2003; 201: 89–96
   PubMed Web of Science ®Google Scholar
• Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, Naito Y, Yoshikawa T. Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperthermia 2009; 25: 210–219
   PubMed Web of Science ®Google Scholar
• Cusack JC, Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS, Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappa B inhibition. Cancer Res 2001; 61: 3535–3540
   PubMed Web of Science ®Google Scholar
• Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1: 152–160
   PubMed Web of Science ®Google Scholar
• Hochwald SN, Lind DS, Malaty J, Copeland EM, 3rd, Moldawer LL, MacKay SL. Antineoplastic therapy in colorectal cancer through proteasome inhibition. Am Surg 2003; 69: 15–23
   PubMed Web of Science ®Google Scholar
• Fady C, Gardner A, Jacoby F, Briskin K, Tu Y, Schmid I, Lichtenstein A. Atypical apoptotic cell death induced in L929 targets by exposure to tumor necrosis factor. J Interferon Cytokine Res 1995; 15: 71–80
   PubMed Web of Science ®Google Scholar
• Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988; 141: 2629–2634
   PubMed Web of Science ®Google Scholar
• Matthews N, Neale ML, Jackson SK, Stark JM. Tumour cell killing by tumour necrosis factor: Inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. Immunology 1987; 62: 153–155
   PubMed Web of Science ®Google Scholar
• Yamauchi N, Kuriyama H, Watanabe N, Neda H, Maeda M, Niitsu Y. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res 1989; 49: 1671–1675
   PubMed Web of Science ®Google Scholar
• Zimmerman RJ, Chan A, Leadon SA. Oxidative damage in murine tumor cells treated in vitro by recombinant human tumor necrosis factor. Cancer Res 1989; 49: 1644–1648
   PubMed Web of Science ®Google Scholar
• Dai S, Jiang L, Wang G, Zhou X, Wei X, Cheng H, Wu Z, Wei D. Hsp70 interacts with TRAF2 and differentially regulates TNF alpha signalling in human colon cancer cells. J Cell Mol Med 2010; 14: 710–25
   PubMedGoogle Scholar
• Beere HM. ‘The stress of dying’: The role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004; 117: 2641–2651
   PubMed Web of Science ®Google Scholar
• Liossis SN, Ding XZ, Kiang JG, Tsokos GC. Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J Immunol 1997; 158: 5668–5675
   PubMedGoogle Scholar
• Chant ID, Rose PE, Morris AG. Susceptibility of AML cells to in vitro apoptosis correlates with heat shock protein 70 (hsp 70) expression. Br J Haematol 1996; 93: 898–902
   PubMed Web of Science ®Google Scholar
• Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C. Heat shock proteins: Essential proteins for apoptosis regulation. J Cell Mol Med 2008; 12: 743–761
   PubMed Web of Science ®Google Scholar
• Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008; 1785: 182–206
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicityand morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14: 224–231
   PubMedGoogle Scholar
• Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 1995; 107: 1074–1082
   PubMed Web of Science ®Google Scholar
• Lewis JM, Sander G, Reintgen D, Letson DG. Hyperthermic limb perfusion: Evolving concepts in the treatment of extremity soft tissue sarcoma. Curr Opin Orthop 2006; 17: 1–5
   Google Scholar
• Weiberdink J, Benckhuysen C, Braat R, Van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905–910
   PubMedGoogle Scholar
• Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008; 24: 193–203
   PubMed Web of Science ®Google Scholar
• Möller MG, Lewis JM, Dessureault S, Zager JS. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia 2008; 24: 275–289
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756–764
   PubMed Web of Science ®Google Scholar